1,537
Views
10
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Hypertriglyceridemia: An underdiagnosed side effect of Capecitabine chemotherapy

, &
Pages 262-263 | Received 16 Sep 2009, Accepted 28 Aug 2009, Published online: 26 Jan 2010

References

  • Pejic RN, Lee DT. Hypertriglyceridemia. J Am Board Fam Med 2006;19:310–6.
  • Roche pharmaceuticals (2007) Package insert. Xeloda (capecitabine). MoH approved leaflets July 2007.
  • Jones KL, Valero V. Capecitabine-induced pancreatitis. Pharmacotherapy 2003;23:1076–8.
  • Sela GB, Haim N. Uncontrolled hypertriglyceridemia induced by capecitabine: Case report and review of the literature. Cancer Chemother pharmacol 2009;63:779–82.
  • Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP. Capecitabine-induced hypertriglyceridemia: A report of two cases. Anticancer Res 2006;26:2249–52.
  • Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N. Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother 2006;40:328–31.
  • Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J, Deliconstantinos G. Capecitabine (xeloda) as monotherapy in advanced breast and colorectal cancer: Effectiveness and side-effects. Anticancer Res 2007;27:1653–6.
  • Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN, Dontas IA, Karamanos BG, Karayiannacos PE. . Influence of 5-fluorouracil on serum lipids. Acta Oncol 1995;34:253–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.